Borg, Sixten, et al. “Cost Effectiveness of Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma in Sweden”. Acta Oncologica, vol. 55, no. 5, May 2016, pp. 554-60, doi:10.3109/0284186X.2015.1096021.